ea0063p256 | Pituitary and Neuroendocrinology 1 | ECE2019
Russo Lucia
, Mazzocut Sara
, Dassie Francesca
, Parolin Matteo
, Martini Chiara
, Carlo Eugenio De
, Fallo Francesco
, Mioni Roberto
, Vettor Roberto
, Maran Alberto
, Maffei Pietro
Background: Pasireotide LAR is a multireceptor targeted somatostatin analogue that has been shown to obtain a better biochemical control of acromegaly. However, pasireotide LAR could induce hyperglycemia in acromegalic patients with higher baseline glucose values. The devices that can track interstitial glucose levels such as continuous glucose monitoring (CGM) could be a useful for studying the impact of SSA on patientsÂ’ glucose status.Aim: We aime...